Literature DB >> 9630046

Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis.

P Niaudet1, R Habib.   

Abstract

Between 1980 and 1994, 38 children with severe forms of Schönlein-Henoch purpura glomerulonephritis were entered into a prospective study to evaluate methylprednisolone pulse therapy on the outcome of nephropathy in terms of clinical symptoms and histopathological changes. The patients were considered at risk of developing chronic renal failure when they presented with a nephrotic syndrome and/or had 50% or more crescentic glomeruli. Initial renal biopsies were obtained from all patients and revealed diffuse proliferative endocapillary glomerulonephritis in 2, focal and segmental glomerulonephritis in 4, and endo- and extracapillary glomerulonephritis in 32, 21 of whom had 50% or more glomeruli with crescents. Patients were treated with intravenous pulse methylprednisolone (3 days) followed by oral prednisone (3.5 months). At the latest follow-up, 1-16 years after initiation of therapy, 27 children had clinically recovered, 3 showed minimal urinary abnormalities, 4 persistent nephropathy, and 4 had progressed to end-stage renal failure. Sequential renal biopsies were obtained from 30 patients, 7-25 months after initiation of therapy. The clinical outcome correlated well with of the activity (hypercellularity, cellular and fibrocellular crescents, and interstitial edema with mononuclear cell infiltrates) and the chronicity (fibrous crescents, glomerular sclerosis, tubular atrophy, and interstitial fibrosis) indexes of post-therapy biopsies. Of particular interest were the post-therapy biopsies of the 18 patients who clinically recovered. They showed a significant decrease of the activity index from 5.1+/-1.1 to 0.4+/-0.8 with a decrease or even a disappearance of IgA deposits, while the chronicity index remained low (0.4+/-0.8 compared with 1.4+/-1). Although uncontrolled, our study suggests that methylprednisolone pulse therapy is effective in those patients at risk of progression of their nephropathy, especially if started early during the course of the disease before the crescents become fibrous.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630046     DOI: 10.1007/s004670050446

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  70 in total

Review 1.  Henoch-Schönlein purpura.

Authors:  E J Tizard
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

2.  Penile involvement in Henoch-Schonlein purpura.

Authors:  J Sandell; R Ramanan; D Shah
Journal:  Indian J Pediatr       Date:  2002-06       Impact factor: 1.967

3.  [17 year old patient with acute abdominal pain, hematochezia and exanthema].

Authors:  D Dürr; R Baia; R Maurer; S Lautenschlager; A Schnider; M Fliegner
Journal:  Internist (Berl)       Date:  2005-06       Impact factor: 0.743

4.  Role of mesangial fibrinogen deposition in the pathogenesis of crescentic Henoch-Schonlein nephritis in children.

Authors:  J I Shin; J M Park; Y H Shin; J S Lee; H J Jeong
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

5.  Cardiac manifestations of Henoch-Schoenlein purpura: IgA mediated vasculitis or Rheumatic fever?

Authors:  Jae Il Shin; Ji Hong Kim; Jae Seung Lee; Dong Soo Kim; Jae Young Choi; Jun Hui Sul
Journal:  Eur J Pediatr       Date:  2006-09-19       Impact factor: 3.183

Review 6.  Treatment-based literature of Henoch-Schönlein purpura nephritis in childhood.

Authors:  Marco Zaffanello; Vassilios Fanos
Journal:  Pediatr Nephrol       Date:  2008-12-09       Impact factor: 3.714

7.  Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch-Schönlein purpura nephritis.

Authors:  Jean-Claude Davin; Rosanna Coppo
Journal:  Pediatr Nephrol       Date:  2013-07-09       Impact factor: 3.714

8.  The ISKDC classification and a new semiquantitative classification for predicting outcomes of Henoch-Schönlein purpura nephritis.

Authors:  Mikael Koskela; Elisa Ylinen; Elli-Maija Ukonmaanaho; Helena Autio-Harmainen; Päivi Heikkilä; Jouko Lohi; Outi Jauhola; Jaana Ronkainen; Timo Jahnukainen; Matti Nuutinen
Journal:  Pediatr Nephrol       Date:  2017-02-14       Impact factor: 3.714

9.  Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis.

Authors:  Ke Xu; Lili Zhang; Jie Ding; Suxia Wang; Baige Su; Huijie Xiao; Fang Wang; Xuhui Zhong; Yanming Li
Journal:  J Nephrol       Date:  2017-11-28       Impact factor: 3.902

Review 10.  Small vessel vasculitis.

Authors:  Paul Brogan; Despina Eleftheriou; Michael Dillon
Journal:  Pediatr Nephrol       Date:  2009-11-03       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.